NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the U.S., but work hard to maintain easy access and all the efficiencies of a smaller operation.

NeoGenomics has been serving the cancer community for over 12 years. We welcomed the expertise of our peers at Clarient Diagnostic Services through acquisition of that company in December 2015.

NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016[neogenomics.com